Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma.
Transcatheter arterial embolization (TAE) destroys a tumor by the induction of necrosis and/or apoptosis and causes inflammation with cytokine production, which may favor immune activation and presentation of tumor-specific antigens. In the current study, we attempted to identify the effect of TAE on tumor-specific T-cell responses and the additional effect of dendritic cell (DC) infusion performed during TAE. The prevalence of tumor antigen-specific T cells was determined by interferon-gamma enzyme-linked immunospot analysis using alpha-fetoprotein (AFP) and tumor antigen-derived peptides in 20 and 13 patients with hepatocellular carcinoma (HCC) who received TAE and TAE with DC infusion, respectively. The increased frequency of AFP-specific T cells was observed in 6 of 20 patients after TAE. It was observed more frequently in patients with DC infusion than in those with TAE alone. However, tumor recurrence was not completely prevented in patients albeit displayed enhanced immune responses. The evidence that the enhanced immune responses were transient and attenuated within 3 months was provided in time-course analysis. In conclusion, TAE with DC infusion enhances the tumor-specific immune responses more effectively than TAE alone. Although the effect is not sufficient to prevent HCC recurrence, these results may contribute to the development of novel immunotherapeutic approach for HCC.
Mizukoshi
Eishiro
E
Department of Disease Control and Homeostasis, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Nakamoto
Yasunari
Y
Arai
Kuniaki
K
Yamashita
Tatsuya
T
Mukaida
Naofumi
N
Matsushima
Kouji
K
Matsui
Osamu
O
Kaneko
Shuichi
S
D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000276:immunology* / Q000628:therapy; D003713:Dendritic Cells / Q000276:immunology*; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D008113:Liver Neoplasms / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000276:immunology
D000509:alpha-Fetoproteins; D007371:Interferon-gamma